==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

Th1205 details
Primary information
ID1814
ThPP IDTh1205
Therapeutic Peptide/Protein NameObiltoxaximab
SequenceNA view full sequnce in fasta
Functional ClassificationIIIa
Molecular Weight148000
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionObiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin. Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.
Indication/DiseaseInvestigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
PharmacodynamicsNA
Mechanism of ActionETI-204 is an affinity-enhanced, de-immunized antibody, which means that its ability to bind to its target pathogen has been strengthened and that elements that might cause an immune response have been removed. ETI-204 targets and binds to Protective Antigen, which prevents the anthrax toxins from binding to and entering the cells in the body, thereby preventing death.
ToxicityNA
MetabolismNA
AbsorptionMean Cmax and AUCinf were 400 ± 91.2 mcg/mL and 5170 ± 1360 mcg•day/mL, respectively.
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameAnthim
CompanyElusys Therapeutics, Inc.
Brand DiscriptionObiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin.
Prescribed forANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.; Also is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate.
Chemical NameNA
FormulationSolution
Physcial AppearanceLiquid
Route of AdministrationIntravenous infusion
Recommended DosageThe recommended dosage of ANTHIM in adult patients is a single dose of 16 mg/kg administered intravenously over 90 minutes (1 hour and 30 minutes); For adult patients weighing less than 40 kg.
ContraindicationNA
Side EffectsHypersensitivity and Anaphylaxis
Useful Linkhttp://www.rxlist.com/anthim-drug/side-effects-interactions.htm
PubMed ID27925405, 27568215, 27431222, 27431219, 27313431, 27085536, 26651519, 25484055, 25484055
3-D StructureN.A.